<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01849341</url>
  </required_header>
  <id_info>
    <org_study_id>ROFLU2011</org_study_id>
    <nct_id>NCT01849341</nct_id>
  </id_info>
  <brief_title>Roflumilast Safety Administered Once a Day on Alternate Days for Two Weeks Compared to the Usual Dosage Once Daily</brief_title>
  <acronym>ROFLU2011</acronym>
  <official_title>Clinical Trial Phase III Blind, Parallel Group to Analyze Differences in the Safety of Roflumilast Administered Once a Day on Alternate Days for Two Weeks Compared to the Usual Dosage Once Daily</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundación Pública Andaluza Progreso y Salud</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is a phase IV clinical trial: longitudinal, prospective, evaluator-blind, randomized into
      2 groups of patients with chronic obstructive pulmonary disease (COPD). The intervention
      group was based on the administration of roflumilast 500 mcg per day on alternate days
      (roflumilast 500μg eod) for 2 weeks (phasing). In the control group assigned to undertake the
      treatment according to the standard dosage (roflumilast 500μg od).

      The patient monitoring will be done by one of the sub-investigators fully independent team
      that started the medication keeping the pattern masking by single blind, and since it aims to
      assess the frequency of adverse events (AEs) in both groups were collected systematically
      different AEs and their characteristics at 15 days (V1), and from that moment a month (V2)
      and 2 months (V3). Likewise, other data collected (functional demographic, comorbidities,
      home treatment, anxiety and depression and quality of life).

      The purpose of this study is to assess whether the administration of roflumilast by a gradual
      pattern varies the incidence of discontinuations due to adverse events when compared with the
      usual dosage.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Actual">July 2014</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference of Adverse Events</measure>
    <time_frame>2 weeks</time_frame>
    <description>Difference in the proportion of patients who leave the study for AEs between the control group (roflumilast 500μg od) and intervention (roflumilast 500μg eod)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patients who leave the study</measure>
    <time_frame>two weeks</time_frame>
    <description>Difference in the proportion of patients who leave the study for AEs between the control group (roflumilast 500μg od) alternating pattern (in patients with impaired tolerance) and intervention (roflumilast 500μg eod) between visits V2 and V0.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">105</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease (COPD)</condition>
  <arm_group>
    <arm_group_label>Roflumilast alternated days</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention: 500 mcg per day on alternate days (roflumilast 500μg eod) for 2 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Roflumilast 500 mcg per day</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Roflumilast 500μg standard dosage</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Roflumilast alternated days</intervention_name>
    <description>500 mcg per day on alternate days (roflumilast 500μg eod) for 2 weeks</description>
    <arm_group_label>Roflumilast alternated days</arm_group_label>
    <other_name>schedule change</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Roflumilast 500 mcg per day</intervention_name>
    <arm_group_label>Roflumilast 500 mcg per day</arm_group_label>
    <other_name>Standard dosage</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of COPD in severe degree GOLD criteria, assessed by post-bronchodilator
             spirometry (FEV1 &lt;50%, FEV1/Forced vital capacity (FVC) &lt;70% of theory).

          -  Age over 18 years.

          -  Productive cough recurrently most days for at least three months a year and at least 2
             consecutive years.

          -  History from smoking prior&gt; 15 to 20 packs / year.

          -  An exacerbation in the previous year.

          -  Stability clinic in the last 30 days.

        Exclusion Criteria:

          -  Pregnancy / breastfeeding.

          -  Acute infections.

          -  Patients with severe mental disorder or uncontrolled, in the opinion of the
             investigator, would make the patient has a higher risk due to their participation in
             the study, could be a confounding factor in the study's results or is likely to
             prevent that the patient meets the requirements of the study or to complete the study.

          -  Patients cachectic or the risk of cachexia.

          -  HIV infection.

          -  Severe immune Infections (systemic lupus erythematosus, multiple sclerosis, etc.).

          -  Gastroesophageal reflux symptoms and diagnosis established.

          -  Hiatal hernia.

          -  Peptic ulcer disease.

          -  Inflammatory bowel pathology.

          -  Neoplastic pathology: current diagnosis of cancer other than basal cell or squamous
             cell carcinoma of the skin.

          -  Moderate to severe hepatic impairment (Child-Pugh BC).

          -  Inability to understand / perform the techniques.

          -  Home treatment with theophylline, methotrexate, azathioprine, infliximab, etanercept,
             inducers of cytochrome P450 (eg, rifampicin, phenobarbital, carbamazepine,
             phenytoin),cytochrome P450 3A4 (CYP3A4) inhibitors (erythromycin and ketoconazole),
             oral contraceptives (gestodene and ethinyl estradiol), making prolonged oral
             corticosteroids, or a drug that contains fluvoxamine, enoxacin and cimetidine.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Teodoro Montemayor Rubio, M.D. Ph D</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital Universitario Virgen Macarena</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ruth Ayerbe, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Complejo Hospitalario de Especialidades Juan Ramón Jimenez</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gregorio Soto, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital de Jerez</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Francisco L Muñoz, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario Reina Sofía</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Concepción Morales, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>H.U. Virgen de las Nieves</affiliation>
  </overall_official>
  <overall_official>
    <last_name>José L de la Cruz, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Complejo Hospitalario Carlos Haya</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Cristina García, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario de Puerto Real</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bernardino Alcázar, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>HAR de Loja</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rosa Vazquez, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Infanta Elena</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital de Jerez</name>
      <address>
        <city>Jerez de la Frontera</city>
        <state>Cádiz</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Reina Sofía</name>
      <address>
        <city>Córdoba</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H.U. Virgen de las Nieves</name>
      <address>
        <city>Granada</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen Macarena</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 6, 2013</study_first_submitted>
  <study_first_submitted_qc>May 7, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 8, 2013</study_first_posted>
  <last_update_submitted>July 7, 2015</last_update_submitted>
  <last_update_submitted_qc>July 7, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 8, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COPD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

